Prostate Cancer, Version 3.2024
Edward M. Schaeffer(Northwestern University), Deborah A. Freedman-Cass(National Comprehensive Cancer Network), Thomas Guzzo(UPMC Hillman Cancer Center), Joseph E. Ippolito(Washington University in St. Louis), Joshua M. Lang(University of Wisconsin–Madison), Shilpa Gupta(Cleveland Clinic), Todd M. Morgan(University of Michigan), Jonathan D. Tward(University of Utah), Tyler P. Robin(University of Colorado Anschutz Medical Campus), Julio M. Pow‐Sang(Moffitt Cancer Center), Heather H. Cheng(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Nabil Adra(Indiana University Health), Rana R. McKay(University of California San Diego), Rhonda L. Bitting(Cancer Research Institute of the Slovak Academy of Sciences), Richard K. Valicenti(Comprehensive Blood & Cancer Center), R. Jeffrey Karnes(Mayo Clinic), Anthony V. D’Amico(Brigham and Women's Hospital), Jenna Snedeker(National Comprehensive Cancer Network), Daniel E. Spratt(University Hospitals Seidman Cancer Center), Russell Z. Szmulewitz(University of Chicago), Neil Desai(Southwestern Medical Center), Brian F. Chapin(The University of Texas MD Anderson Cancer Center), Robert E. Reiter(University of California, Los Angeles), Stan Rosenfeld(Office of Patient Care Services), Benjamin A. Teply(Susan Thompson Buffett Foundation), Mack Roach(University of California, San Francisco), Tanya B. Dorff(City Of Hope National Medical Center), Xīn Gào(Qingdao University), Yi An(Yale University), J.K. Wong(Fox Chase Cancer Center), Thomas A. Farrington(Health Net), Sandy Srinivas(Stanford University), Michael Kuettel, Ahmad Shabsigh(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), James A. Eastham(Memorial Sloan Kettering Cancer Center), Tamara L. Lotan(Johns Hopkins University)
Cited by 289
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k